Equities
Health CareMedical Equipment and Services
  • Price (USD)248.35
  • Today's Change4.13 / 1.69%
  • Shares traded847.69k
  • 1 Year change+13.28%
  • Beta1.0526
Data delayed at least 15 minutes, as of Feb 13 2026 21:00 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

STERIS Plc is a provider of products and services that support patient care with an emphasis on infection prevention. Its segments include Healthcare, Applied Sterilization Technologies (AST), and Life Sciences. Its Healthcare segment provides a comprehensive offering for healthcare providers worldwide, focused on sterile processing departments and procedural centers, such as operating rooms and endoscopy suites. AST segment supports medical device and pharmaceutical manufacturers through a global network of contract sterilization and laboratory testing facilities, and integrated sterilization equipment and control systems. Its Life Sciences segment provides a comprehensive offering of products and services designed to support biopharmaceutical and medical device research and manufacturing facilities, in particular those focused on aseptic manufacturing. Its portfolio includes a full suite of consumable products, equipment maintenance, specialty services, and capital equipment.

  • Revenue in USD (TTM)5.83bn
  • Net income in USD708.66m
  • Incorporated2016
  • Employees17.79k
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
STE:NYQ since
announced
Transaction
value
Medik Hospital Design GmbHDeal completed01 Dec 202501 Dec 2025Deal completed-6.73%--
Data delayed at least 15 minutes, as of Feb 13 2026 21:00 GMT.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Penumbra Inc1.33bn164.03m13.31bn4.50k81.879.7873.379.984.144.1433.6334.700.82761.077.42296,399.6010.181.4211.311.5866.8063.2112.301.964.18--0.01710.0012.8616.89-84.59-21.98-0.853--
Align Technology Inc4.03bn410.35m13.40bn20.95k33.013.3132.683.325.665.6655.5856.430.64835.333.85--6.598.119.6711.9768.2570.4010.1712.311.24------0.89910.30-2.61-25.40----
Guardant Health Inc902.57m-398.79m13.51bn2.00k------14.97-3.21-3.217.27-2.840.64114.028.85451,510.30-28.33-24.20-33.49-26.8363.7663.23-44.18-91.243.12-10.701.47--31.0428.088.98--10.58--
Cooper Companies Inc4.09bn374.90m16.26bn15.00k44.291.9721.623.971.871.8720.4642.060.33121.715.29272,826.703.038.043.328.8665.5466.019.1624.661.136.320.23320.20495.0610.98-4.449.483.15--
Hologic Inc4.13bn543.80m16.75bn7.07k31.143.1919.964.062.412.4118.2823.510.46082.576.79583,663.406.0711.226.8212.8556.5160.2013.1821.993.3215.760.32460.001.741.66-28.35-12.69-0.5168--
Insulet Corp2.52bn246.20m17.08bn3.90k70.4312.3451.176.773.453.4534.8519.680.8331.626.02646,641.008.136.0010.057.0371.4667.059.769.222.1827.390.4230.0022.0722.92102.76104.84-4.75--
Illumina Inc4.34bn850.00m17.86bn8.60k21.326.5615.954.115.485.4827.8817.800.67092.615.34505,000.0013.13-10.1517.32-12.1566.6165.3919.57-23.181.7215.790.4221---0.66336.04169.505.32-4.77--
West Pharmaceutical Services Inc3.07bn493.70m18.04bn10.60k36.875.6827.725.876.796.7942.2844.110.77694.805.46--12.1115.2414.2918.1935.9137.8915.5918.672.34--0.069.996.257.440.2037.3610.395.51
Zimmer Biomet Holdings Inc8.23bn705.00m19.11bn17.00k27.201.5010.632.323.553.5541.4264.110.37031.105.17--3.173.033.583.4669.7171.018.569.101.104.740.371829.107.206.08-21.98--9.260.00
Steris PLC5.83bn708.66m24.36bn17.79k34.563.4120.354.187.197.1859.0972.930.56584.926.12327,662.406.915.047.595.5144.1143.7512.2110.691.7520.990.209437.516.2412.4910.648.4011.528.99
DexCom Inc4.52bn720.70m26.95bn10.30k39.5910.0227.925.971.771.7711.086.990.65193.024.28438,436.9010.408.7916.4111.7560.2064.9715.9614.901.38--0.47850.0011.3422.276.4141.6314.79--
Veeva Systems Inc3.08bn860.33m28.62bn7.29k33.874.0631.809.295.145.1418.4142.840.4234--9.15422,472.4011.8311.3313.5014.3575.6772.6027.9323.96----0.000.0016.2019.9935.8418.8536.56--
Waters Corp3.17bn642.63m31.72bn7.60k30.0412.3837.3510.0210.7710.7753.0326.110.65692.464.05--13.3417.0314.5320.6859.2859.0120.3022.40--16.770.3546--6.996.000.75184.26-8.14--
Data as of Feb 13 2026. Currency figures normalised to STERIS plc's reporting currency: US Dollar USD

Institutional shareholders

38.44%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 31 Dec 202511.31m11.53%
BlackRock Fund Advisorsas of 31 Dec 20255.78m5.89%
SSgA Funds Management, Inc.as of 31 Dec 20254.61m4.70%
Massachusetts Financial Services Co.as of 31 Dec 20253.26m3.32%
Morgan Stanley Investment Management Ltd.as of 31 Dec 20252.59m2.64%
Geode Capital Management LLCas of 31 Dec 20252.52m2.57%
Generation Investment Management LLPas of 31 Dec 20252.09m2.13%
Orbis Investment Management Ltd.as of 30 Sep 20252.04m2.08%
Select Equity Group LPas of 30 Sep 20251.98m2.01%
Mitsubishi UFJ Asset Management Co., Ltd.as of 31 Dec 20251.54m1.57%
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.